The Global Challenge of Colistin Resistance – Recent Evidence from Romania and Elsewhere

The Global Challenge of Colistin Resistance – Recent Evidence from Romania and Elsewhere. Biomed J Sci & Tech Res The increasing resistance of Gram-negative bacilli to a wide range of antibiotics has driven a return to colistin as the last resort in the treatment of severe infections. Given the stakes of colistin efficiency at both the individual level and generally, the manifestation and mechanisms of resistance to polymyxin E (also known as colistin) are now subject to careful monitoring and research. Recent findings from different parts of the world including Romania are reviewed and discussed in the light of ensuing challenges.


Colistin and Colistin Resistance
Colistin is a cationic polypeptide antibiotic from the polymyxin family, which includes polymyxin E (colistin) and polymyxin B.
It was discovered in 1947 when it was isolated from the bacillus Paenibacillus polymyxa subsp. colistinus [1,2]. Its main activity mechanisms involve the displacement of calcium and magnesium ions from lipopolysaccharides, leading to a disruption in the permeability of the outer cellular membrane, as well as the inhibition of the type II NADH-quinone oxidoreductases, which is a crucial respiratory enzyme in the inner membrane of the Gram-negative strains [3,4]. Polymyxin E exerts a swift and strong bactericidal effect on Pseudomonas aeruginosa, Acinetobacter baumannii, and most bacilli from the Enterobacterales family, except for Proteus spp., Providencia spp., Serratia spp., Morganella spp., which are naturally resistant to colistin [5]. Mutations and adaptation are the most important mechanisms of bacterial acquired resistance to polymyxin E. Because LPS is the major target of colistin it is clearly that the first mechanisms of resistance will appear at this level [5,6]. For Klebsiella pneumoniae strains, the modification of the mgrB gene is the most important mechanism of resistance to colistin [7].
Regarding A. baumannii strains, the alteration of the lpxA, lpxC and lpxD genes determine inhibition of lipid A synthesis and, as a consequence, colistin will lose the binding to bacterial cell [8]. of a combination of both [5]. Prior to 2015, resistance to colistin was explained by means of chromosomal mutations, but then new research uncovered genetic resistance that can be plasmid-mediated [9]. Over the last years, for Escherichia coli and K. pneumoniae strains have been reported plasmid mediated resistance genes, mcr, which encodes phosphoethanolamine transferase [10]. Traditional microbiology methods, as well as phenotyping and molecular biology techniques, are some of the ways in which resistance to colistin may be highlighted, the gold standard in this regard being the broth microdilution test. Recent evidence and epidemiologic studies have helped raise the alarm among the medical community and add a shared sense of urgency to the conversation. all-cause mortality rates raised from 13% and 32%, respectively, to 15% and 38%, respectively. The mechanisms of polymyxin resistance were heterogenous, leading to the conclusion that, in most occasions, polymyxin-resistant strains emerge after colistin treatment rather than clonal dissemination.

Evidence of Increasing Colistin Resistance
According to a recent study, no fewer than 590 strains of colistin-resistant K. pneumoniae were identified in six countries: 438 in Turkey, 86 in Iran, 24 in Saudi Arabia, 31 in the United Arab Emirates, 5 in Kuwait, 3 in Israel, and another 3 in Lebanon, between 2013 and 2018. The mgrB gene was found to be involved in the resistance mechanism [17]. In another study from 2020, in Turkey, from a total of 150 strains of Enterobacterales isolated in pediatric patients suffering from infections, 41% were resistant to carbapenems and 15% to colistin. The reported risk factors for colistin resistance in these cases were mechanical ventilation, urinary catheterization, and the associated pathology of necrotizing enterocolitis [18]. The presence of the gene mcr-1 and colistin resistance were monitored over a 5-year period (2014-2019) in patients infected with carbapenem-resistant Enterobacterales strains, who were administered colistin as part of their treatment.
At the beginning, the incidence of strains carrying the mcr-1 gene was low (0.41%), but then it began to rise (1.38%), especially once colistin was introduced. This pointed to the hypothesis that polymyxin E was responsible for triggering the mcr-1 gene. The fact that the colistin minimal inhibitory concentration increased from <2 mg/L in 80% of the strains to 2 mg/L in 100% of the strains in a relatively short amount of time was yet another reason of concern [19].
In India, by 2020, 2499 strains of Klebsiella spp. were isolated from urine, sputum, broncho-alveolar lavage, blood culture and pus, in patients hospitalized in intensive care unit; 8.75% of colistinresistant Klebsiella spp. were isolated from blood specimens, 4.26% from urine samples and 4.4% from sputum [20]. Another

Colistin Resistance in Romania
In Romania, in 2015, the presence of four colistin-resistant K.
pneumoniae strains with identical PFGE profiles (Pulse-field Gel Electrophoresis) was reported in the cardiac intensive care unit at a university hospital in North-Eastern Romania. Fortunately, they did not produce carbapenemases [22]. However, in a recent study on patients with urinary tract infections, approximately 30% of K. pneumoniae isolates were found to be colistin-resistant and to produce wide-spectrum beta-lactamases [23]. Close monitoring and additional studies are needed in order to attain a more comprehensive understanding of the phenomenon and plan accordingly before the problem aggravates.

Conclusion
The increasing prevalence of multidrug-resistant strains has substantial, far-reaching negative implications for the entire world. The still excessive use of antibiotics and their diminishing effectiveness can limit treatment options to colistin, which we now know is not invulnerable. Invasive medical procedures and prolonged hospitalization can further contribute to the risk of developing resistance to this life-saving medication. In countries like Romania, where data is still scarce but sufficiently concerning, more research and communication need to be conducted with an adequate sense of urgency.